샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514174

방광암 치료제 시장

Bladder Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 283 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

방광암 치료제 시장은 2030년까지 3억 4,530만 달러에 달할 전망입니다.

2023년에 2억 5,500만 달러로 평가된 방광암 치료제 시장은 2030년에는 3억 4,530만 달러에 이를 전망이며, 예측 기간 동안 복합 연간 성장률(CAGR) 4.4%로 성장할 것으로 예측됩니다. Transitional Cell 방광암 치료제는 본 보고서에서 분석한 부문 중 하나이며 복합 연간 성장률(CAGR) 3.9%로 성장을 지속하고, 분석 기간 종료 시에는 1억 1,460만 달러에 달할 것으로 예측되고 있습니다. 비근육 침습성/표재성 방광암 치료제 부문의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 5.2%로 추정됩니다.

미국 시장은 6,890만 달러로 추정되며 중국은 복합 연간 성장률(CAGR) 7.3%로 성장할 것으로 예측됩니다.

미국의 방광암 치료제 시장은 2023년 6,890만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 예측 기간 동안 복합 연간 성장률(CAGR) 7.3%로 성장하여 2030년에는 7,220만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 2.3%와 3.6%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 2.9%로 성장할 것으로 예측됩니다.

세계 방광암 치료 시장 - 주요 동향과 촉진요인 요약

방광암(BCa)은 비뇨기계에서 가장 유병률이 높고, 경제적으로도 부담이 큰 악성 종양의 하나로 인식되고 있으며, 재발률과 진행률이 높은 것으로 지적되고 있습니다. 방광암 치료제 시장은 인구통계학적, 기술적, 임상적 요인의 조합에 의해 견인되고 있습니다. 많은 암과 마찬가지로 방광암 치료법의 개발과 개량은 현재 진행중인 연구 발견, 검진 증가, 고령화에 의해 영향을 받습니다. 방광암 치료제 시장의 주요 촉진요인은 세계 이환율의 상승입니다. 인구 고령화, 특정 화학물질 노출, 흡연, 기타 라이프스타일 위험 등의 요인은 방광암의 증례 수 증가에 기여하고 있습니다. 이 증가는 당연히 효과적인 치료에 대한 수요를 촉진합니다. 유망한 방광암 치료제에 대한 패스트 트랙 지정이나 승인 등 정부의 지원 정책이 기술 혁신을 촉진하고 시장에서 신약의 이용을 촉진하고 있습니다. 게다가 관민 쌍방으로부터의 암 연구에의 자금 원조가 세계적으로 증가해, 새로운 치료법의 개발이 촉진되고 있습니다.

방광암의 치료와 관리는 학제간 연구와 기술 혁신에 힘입어 특히 진단과 치료 접근법에서 현저한 진보를 이루고 있습니다. 표적 치료, 면역요법, 비침습적 진단 바이오마커의 최근 동향은 유망하며, 보다 개별화되고 효과적이고 침습적이지 않은 치료 옵션으로 이어질 수 있습니다. 또한, 분자진단 및 영상 진단과 같은 진단 기술의 진보는 조기 발견 및 정확한 병기 분류에 필수적이며, 이들은 효과적인 치료 및 환자의 예후 개선에 필수적입니다. 소변 바이오마커의 개발은 보다 침습성이 낮은 진단 옵션을 제공하지만, 임상으로의 확산은 여전히 어려우며 추가 검증이 필요합니다.

제약업계와 생명공학산업은 진행기 및 치료 저항성 BCa 환자에게 새로운 희망을 주는 혁신적인 표적 치료제와 면역요법 등 신규 치료제의 개발을 적극적으로 추진하고 있습니다. 방광암 치료에서는 바이오마커와 유전자 서열을 이용하여 개별 환자프로파일에 맞춘 치료를 실시하여 효능을 최적화하고 부작용을 최소화하는 맞춤형 의료가 큰 트렌드가 되고 있습니다. 이 분야가 계속 진화함에 따라 진단의 딥러닝과 AI의 통합은 병용 요법과 암 나노 메디신의 진행중인 연구와 결합하여보다 정교하고 효과적인 환자 중심 치료 전략에 역동적입니다. 시프트를 강조합니다.

조사 대상 기업 예(주목의 전 62사)

  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Pfizer, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Bladder Cancer Therapeutics Market to Reach US$345.3 Million by 2030

The global market for Bladder Cancer Therapeutics estimated at US$255.0 Million in the year 2023, is expected to reach US$345.3 Million by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Transitional Cell Bladder Cancer Therapeutics, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$114.6 Million by the end of the analysis period. Growth in the Non Muscle Invasive / Superficial Bladder Cancer Therapeutics segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.9 Million While China is Forecast to Grow at 7.3% CAGR

The Bladder Cancer Therapeutics market in the U.S. is estimated at US$68.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$72.2 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Bladder Cancer Therapeutic Market - Key Trends and Drivers Summarized

Bladder cancer (BCa) is recognized as one of the most prevalent and financially burdensome malignancies of the urinary system, noted for its high rates of recurrence and progression.  The market for bladder cancer therapeutics is driven by a combination of demographic, technological, and clinical factors.  As with many forms of cancer, the development and refinement of treatments for bladder cancer are influenced by ongoing research discoveries, increased screening, and an aging population. The primary driver for the bladder cancer therapeutics market is the rising incidence of the disease globally. Factors such as aging populations, exposure to certain chemicals and smoking, and other lifestyle risks contribute to the growing number of bladder cancer cases. This increase naturally drives demand for effective treatments. Supportive government policies, including fast-track designations and approvals for promising bladder cancer treatments, encourage innovation and expedite the availability of new drugs in the market. Additionally, increased funding for cancer research from both public and private sectors globally enhances the development of new therapeutic options.

The treatment and management of bladder cancer are undergoing significant advancements, particularly in diagnostic and therapeutic approaches, fueled by interdisciplinary research and technological innovations. Recent developments in targeted therapies, immunotherapy, and non-invasive diagnostic biomarkers are promising, potentially leading to more personalized, effective, and less invasive treatment options. Furthermore, advancements in diagnostic technologies such as molecular diagnostics and imaging techniques are crucial for early detection and accurate staging, which are essential for effective treatment and improved patient outcomes. The development of urinary biomarkers offers a less invasive diagnostic alternative, though widespread clinical integration remains challenging and necessitates further validation.

The pharmaceutical and biotechnology sectors are actively pursuing the development of novel therapeutics for BCa, including innovative targeted therapies and immunotherapies that provide new hope for patients with advanced-stage or treatment-resistant forms of the disease. There is a significant trend towards personalized medicine in bladder cancer treatment, utilizing biomarkers and genetic sequencing to tailor treatments to individual patient profiles, optimizing efficacy and minimizing side effects. As the field continues to evolve, the integration of deep learning and AI in diagnostics, coupled with ongoing research into combination therapies and cancer nanomedicine, underscores a dynamic shift towards more sophisticated, effective, and patient-centered treatment strategies.

Select Competitors (Total 62 Featured) -

  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bladder Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Bladder Cancer Drives Therapeutics Market Growth
    • Growth in Geriatric Population Strengthens Business Case for Bladder Cancer Therapeutics
    • Integration of Personalized Medicine in Cancer Treatment Throws Spotlight on Innovation
    • Advances in Targeted Therapy Propel Market Development
    • Rising Investments in Cancer Immunotherapy Expands Market Horizons
    • Growing Focus on Early Diagnosis and Treatment Spurs Adoption of Bladder Cancer Therapeutics
    • Rising Demand for Combination Therapies in Bladder Cancer. Here is the Story
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Bladder Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Transitional Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Transitional Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Transitional Cell Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Invasive Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Invasive Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Squamous Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Squamous Cell Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Squamous Cell Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Non Muscle Invasive / Superficial Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Bladder Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • JAPAN
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • CHINA
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • EUROPE
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Bladder Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • FRANCE
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • GERMANY
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • INDIA
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 125: India Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: India 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 128: India Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: India 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Bladder Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Bladder Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030
  • AFRICA
    • Bladder Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Bladder Cancer Therapeutics by Type - Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Bladder Cancer Therapeutics by Type - Percentage Breakdown of Value Sales for Transitional Cell Bladder Cancer, Non Muscle Invasive / Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer and Other Types for the Years 2014, 2024 & 2030
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Bladder Cancer Therapeutics by Treatment - Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Bladder Cancer Therapeutics by Treatment - Percentage Breakdown of Value Sales for Surgery, Chemotherapy, Immunotherapy, Radiation Therapy and Other Treatment for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제